Meet a Catalyst Flex Expert Welcome to Catalyst Flex Experts, a series celebrating our experts and their passion for the work they do for our Catalyst Flex clients. These spotlights on our exceptional team showcase each individual’s experience and unwavering dedication toward helping us achieve the Catalyst mission to inspire people to design and deliver better clinical trials.  Lisa Dawson, RN Lisa Dawson, RN, Senior Director, Safety, has more than 16 years of pharmacovigilance experience within the pharmaceutical and clinical research industries. Regulatory compliance is a key focus ..read more

Meet a Catalyst Flex Expert Welcome to Catalyst Flex Experts, a series celebrating our experts and their passion for the work they do for our Catalyst Flex clients. These spotlights on our exceptional team showcase each individual’s experience and unwavering dedication toward helping us achieve the Catalyst mission to inspire people to design and deliver better clinical trials.  Svetlana Kolchinsky For more than 20 years, Svetlana has been a leader in the clinical research industry. From her work as a scientist at the National Institutes of Health (NIH) or the American Red Cross to her ..read more

Network models for large contract research organizations (CROs) tend to focus on high volume and big data. Catalyst Oncology’s early phase site network disrupts the status quo and is a differentiator for our early phase oncology solution, swinging the pendulum in the opposite direction from large CROs. Catalyst Oncology focuses on dedicated relationships with sites and sponsors, site advocacy, and a true understanding of reducing the site burden. Steeped in Catalyst’s corporate values of listening, learning, flexibility, collaboration, and commitment, our site network model is based on quality ..read more

Meet a Catalyst Flex Expert Welcome to Catalyst Flex Experts, a series celebrating our experts and their passion for the work they do for our Catalyst Flex clients. These spotlights on our exceptional team showcase each individual’s experience and unwavering dedication toward helping us achieve the Catalyst mission to inspire people to design and deliver better clinical trials.  Craig has a wealth of experience—nearly two decades as a leader—that he relies on as the leader of Catalyst Flex. With more than 27 years of experience, Craig has a strong understanding in biometrics and data scie ..read more

What is Project Optimus? Project Optimus, an initiative from the FDA, seeks to optimize dosing. Since the released draft guidance in 2023, early phase oncology drug development has shifted to accommodate. As an oncology specialist with significant early phase experience, Catalyst Oncology can help ensure your development plan is Project Optimus ready. 1, 2 What is the effect of Project Optimus? Oncology clinical development has historically focused Phase I trials around the goal of determining a maximum tolerated dose (MTD). With the industry moving past chemotherapy to the advancement of targ ..read more

Expanding on some of the highlights from the conference By Ershlena McDaniel, Senior Director, Resourcing Operations, Catalyst Flex The PHUSE US Connect 2024 conference was nothing short of empowering, engaging, and enlightening. Connecting with like-minded professionals who also share a deep commitment and passion for the clinical trial process while keeping patients the number one priority was a highlight. A recurring theme that resonated across multiple presentations and discussions revolved around artificial intelligence (AI) and machine learning (ML) and its impact on clinical trials.&nbs ..read more

Exploratory data analysis (EDA) in clinical research involves analyzing and summarizing data to extract insights, identify patterns, and produce hypotheses—all of which are essential for guiding subsequent research directions. In this poster presentation from Phuse US 2024, EDA seeks to understand treatment responses, potential correlations, and patient demographics. Researchers investigate data variability, distributions, and correlations between variables via statistical measurements, visualizations, and summary approaches. Data distributions, outliers, and trends are shown by graphical repr ..read more

At Catalyst Clinical Research, our people are the foundation of our organization and culture. Team members live out Catalyst’s core values daily to help create a culture that enables us to do our best work.  Listening: We promote the investment of time to understand the situation and people involved before diving in to solve an issue.  Flexibility: We celebrate diversity in people, ideas, work styles, and our approaches to challenges for which we create solutions. We thrive in an environment that is innovative, not burdened by excessive layers of decision-making, allowing us to rapi ..read more

Clinical trials are the springboard for progress in modern healthcare, guiding the development and evaluation of new treatments and next-generation therapies for patients. Trials exist at the critical juncture where scientific innovation meets real-world patient care and offer the promise of improved health outcomes and an enhanced quality of life. Yet as innovative as clinical trials are, the industry itself is still ripe for innovation from within. The structure and setup of clinical trials, coupled with the technologies that facilitate them, play a pivotal role in shaping their success or f ..read more

Nik Morton assumes CEO role, Nick Dyer pivots to new, expanded leadership position Catalyst Clinical Research announced that Nik Morton assumed its CEO role on 12 February 2024. Prior to this move Nik served as the company’s President and COO. Having joined Catalyst as its COO in 2022. Nik moves into his new position while Nick Dyer, Catalyst’s former CEO, shifts his focus to lead the strategic growth of several companies while overseeing the continued development and evolution of Catalyst and Genpro, businesses within Project Constellation Holdings.  “Nik is an experienced clinical resea ..read more